Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

Brand ambassador programs, a type of influencer marketing, have become a popular way to expand your brand awareness, grow your business, and make more money. And here’s the proof: sixty-eight percent ...

Claude 3.7 Sonnet, the latest AI model from Anthropic, represents a significant advancement in artificial intelligence. With its enhanced reasoning capabilities, exceptional coding proficiency, and ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

This story contains AI-generated text. The author has used AI either for research, to generate outlines, or write the text itself. Dynamic programming is a powerful technique for solving optimization ...